Regeneron's Trading Volume Surges 30.57% to $711 Million Ranking 156th in Market Activity

On July 18, 2025, Regeneron's trading volume reached $711 million, marking a 30.57% increase from the previous day, ranking 156th in the day's stock market activity. Regeneron's stock price fell by 1.36%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that its board of directors has declared a quarterly dividend of $1.15 per share on the company's common stock. The dividend is payable on September 15, 2025, to stockholders of record at the close of business on August 15, 2025. This dividend declaration reflects the company's strong financial performance and commitment to returning value to its shareholders.

Regeneron has also reported positive results from its Phase 3 clinical trial for a new drug candidate aimed at treating a rare genetic disorder. The trial met its primary endpoint, demonstrating a statistically significant improvement in patients' symptoms compared to the placebo group. This success is expected to accelerate the drug's regulatory approval process and expand Regeneron's portfolio of innovative therapies.

Additionally, Regeneron has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize a novel immunotherapy for cancer treatment. The collaboration will leverage Regeneron's expertise in antibody discovery and the partner's advanced cell therapy platform, aiming to bring a groundbreaking treatment to patients with limited therapeutic options.